Advertisement TTY Biopharm to market PharmaMar's Aplidin in Taiwan to treat hematological cancers - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

TTY Biopharm to market PharmaMar’s Aplidin in Taiwan to treat hematological cancers

Spain-based PharmaMar has entered into an exclusive license and commercialization agreement with TTY Biopharm to market and distribute the drug candidate Aplidin (plitidepsin) in Taiwan for the treatment of hematological cancers.

As part of the deal, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by Aplidin.

The deal will see PharmaMar retain exclusive production rights and supply the finished product to TTY Biopharm for commercial use.

Aplidin is PharmaMar’s second anticancer drug candidate obtained from a marine organism and is currently being developed to treat multiple myeloma and a type of T cell lymphoma.

In June, PharmaMar has completed patient enrollment in the international pivotal Phase III trial (ADMYRE) for Aplidin in refractory/relapsed multiple myeloma.

PharmaMar Business Development & Licensing vice-president Heiner Pieper said: "Thousands of patients are living with this disease, and it is our commitment and dedication to bring a novel and first-in-class therapy to patients in need.

"For this mission, we are delighted to collaborate in a partnership with one of the long-standing leaders in the field of oncology and hematology in Taiwan."

Plitidepsin specifically binds to the eEF1A2 and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis.

TTY Biopharm chairman Hsiao Ying-Chun said: "Our understanding of the Taiwanese market and our capabilities to market plitidepsin along with the therapeutic value of this innovative compound will be factored into the success of this partnership.

"We are hoping to start contributing to the well-being of these patients by providing clinicians with a novel drug."

Currently, plitidepsin is in clinical development for hematological cancers, including a Phase III trial in relapsed or refractory multiple myeloma, a Phase Ib trial in relapsed or refractory multiple myeloma as a triple combination of plitidepsin, bortezomib and dexamethasone, and a Phase II trial in relapsed or refractory angioimmunoblastic T-cell lymphoma.

The company has also received orphan drug designation for plitidepsin from the European Medicines Agency (EMA) and the US Food and Drud Administration (FDA).